BLEST Renews Air Quality Compliance Work at Five Air Force Bases Across New Mexico and Arizona

WESTMINSTER, CA / July 1, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator and engineering services solution provider, today announced that its engineering subsidiary, BioLargo Engineering, Science & Technologies (BLEST), has received contract renewals totaling more than $1.4 million over 12 months to continue providing air quality and environmental support services at five U.S. Air Force bases.

BLEST serves as a subcontractor to the primary environmental contractors and performs regulatory compliance, permitting, testing, air data management, compliance reporting, and inventory management. The renewals continue ongoing, multi-year work into their next option year.

"These recurring Air Force contracts give BioLargo a base of repeatable engineering revenue, alongside larger engineering projects such as the pilot-scale mineral processing facility announced in April, as well as the company's ongoing product sales," said Dennis P. Calvert, President and CEO of BioLargo, Inc.

"Our teams have supported air quality and environmental compliance at these specific Air Force bases for years. Renewing this work means continuity for the installations and for the specialists who do it, and that continuity is what our prime-contractor partners rely on," said Randall Moore, President of BioLargo Engineering, Science & Technologies (BLEST).

Additional information about BioLargo is available in the company's filings with the U.S. Securities and Exchange Commission and at their Homepage.

https://preview.redd.it/uwrciczfulah1.jpg?width=1290&format=pjpg&auto=webp&s=c76164a5f12394f79bf5331b178372991bf81536

About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease.

Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.

I’ve been digging into Clyra Medical, and this is one of the cleanest small-cap medtech setups I’ve seen in a while. The combination of FDA clearance, real clinical presentation data, international distribution, and a major global partner still under strict NDA makes this feel like a story the market is not fully pricing in yet.

The setup

There’s a medical device company with:

• FDA-cleared product already in commercial launch.
• Real-world clinical presentation data.
• International distribution across the US, Europe, the Middle East, and North Africa.
• First commercial stocking order already shipped.
• A major global partner relationship still under strict NDA.
• Manufacturing capacity cited at around 2 million units per year.
• An implied valuation that still looks very small relative to the opportunity.

That is a lot of moving parts for a company the market is still treating like a tiny side story.

Why the science matters

ViaCLYR uses a copper-iodine complex designed to deliver broad-spectrum antimicrobial activity while remaining tissue-friendly and persistent enough to matter in real wound care.

What matters here is that this is not just about “killing bugs.” It is about the bigger chronic wound problem:

• biofilm,
• stalled healing,
• drainage,
• slough,
• tissue tolerance,
• and the practical limitations of current topicals.

THE CLYRA ADVANTAGE

ViaCLYR™ uses Copper-Iodine Complex Solution (CICS) technology designed to deliver broad-spectrum antimicrobial activity while remaining tissue-friendly and persistent enough to matter in real clinical workflows.

https://preview.redd.it/t2jec2u7hi7h1.png?width=1226&format=png&auto=webp&s=fcec2f974f7510f50dbb77adf6654f943523529f

Medical advantages:

1. No known resistance

• Copper-iodine complexes are attractive because they are not built on the same resistance-prone paradigm as antibiotics.
• That matters in chronic wound environments where repeated exposure can weaken many conventional approaches.

​

2.Superior biofilm suppression

• Biofilm is one of the biggest reasons chronic wounds fail to heal.
• The Clyra thesis is that this technology can disrupt that barrier more effectively than standard options.

​

3.Faster wound closure

• In the Boswick presentation, clinical experience was described as showing rapid wound transformation and enhanced healing.
• That is a strong signal if it continues to hold in broader clinical adoption.

​

4.Sinus tract closure

• This is one of the harder wound complications to treat.
• The reported results suggest performance in areas where standard care often underperforms.

​

5.No adverse reactions reported in the presented series**

• That matters because a product can be antimicrobial and still be unusable if it irritates tissue or creates practical safety concerns.

​

6.Real-world validation

• This was not presented as a theoretical concept.
• It was described in a multi-site, clinician-driven setting, which is more relevant than isolated lab claims.

The early clinical language from Boswick stood out to me immediately.

Quote callouts

>

>

>

>

That is not the tone of a weak product story.

HOCl vs copper-iodine

One of the most interesting parts of the wound-care discussion is the comparison between HOCl and stoichiometric copper-iodine complexes like the Clyrasept technology used in ViaCLYR.

Why HOCl can be limiting

• It can be useful, but it is more finicky in practice.
• It is sensitive to light and oxygen.
• It can degrade faster than you would like.
• It may be less ideal for difficult chronic wounds where persistence matters.

Why copper-iodine is compelling

• It appears more stable at room temperature.
• It is better suited for predictable use and shelf life.
• It is designed to better penetrate mature biofilm.
• It may be more useful in slough-heavy, fibrotic, stalled wounds.

One clinician’s reaction really summed up the practical angle:

• Even without using HOCl personally, the biofilm penetration advantage looked meaningful.
• That seemed especially relevant in wounds with slough where sharp debridement is hard.
• If a product can work where conventional topicals are less practical, that is a real edge.

Clinical signal from Boswick

The Boswick presentation is one of the strongest validation points in the story.

What was presented:

• Multi-site evaluation.
• Roughly 36 cases.
• Four wound clinics.
• Four-month period.
• Diabetic foot ulcers.
• Venous leg ulcers.
• Pressure injuries.
• Complex surgical wounds.

Reported outcomes:

• Very rapid reduction in wound fluid.
• Early increase in healing activity.
• Faster wound edge improvement.
• Rapid closure or shortening of wound tunnels.
• Dramatic wound transformation.
• No adverse events in the treatment group.

That is the kind of early clinical signal that makes both investors and clinicians pay attention.

Commercial momentum

This is where the story starts to feel more real.

Management said:

• Clyra already shipped its first commercial stocking order.
• Two distributors are under contract.
• Distribution is being built in parallel with the regulatory rollout.
• Al Hikma is now part of the picture.
• Al Hikma covers the GCC, Levant, North Africa, and adjacent markets.
• That region represents more than 500 million people.

Why that matters:

• This is not just a science project.
• This is not just “coming soon.”
• This is a product moving into real channels.

The “gorilla partner”

This may be the biggest validation point of all.

Management said:

• The major global partner is under strict NDA. A $100B+ company
• They are closer to the finish line than ever before.
• They completed a formative and summative human factors validation study.
• The final package is going to the FDA very soon.

Quote callouts

>

>

>

What I take from that:

• The company is in the late-stage packaging and validation phase.
• The partner is real enough to require confidentiality.
• The remaining work sounds procedural and regulatory, not conceptual.
• This is the kind of setup where people either lean in or miss it entirely.

Manufacturing readiness

Another detail that matters:

• DD materials reference around 2 million units per year in manufacturing capacity.
• That suggests the company has already prepared for scale.
• That is much more credible than a “we’ll figure out production later” story.

Why that matters:

• If demand arrives, the product may already have a supply base ready.
• That lowers one of the biggest execution risks in small-cap medtech.
• It helps the commercial story feel more advanced than the market may be pricing in.

Why the valuation stands out

The simple case is this:

• FDA clearance.
• Clinical validation.
• Commercial stocking order.
• International distribution.
• NDA-protected major partner.
• Manufacturing readiness.

And yet the implied valuation still looks small relative to the setup.

The market may be:

• underestimating the rollout,
• missing the clinical significance,
• discounting the NDA partner because it is not public yet,
• or simply not paying attention.

What you get for free

Here is the part that I think is being overlooked the most.

If you look at the parent company, the Clyra story is not the only thing you’re getting exposure to:

• AEC — water tech with real-world validation.
• Battery tech — long-duration storage optionality.
• Engineering business — a profitable engine with operating revenue.
• Odor elimination tech — the platform behind the blockbuster Pooph success.
• Clyra — the wound-care upside many people are focusing on now.

That is the kind of multi-asset setup that makes the current valuation feel detached from the sum of the parts.

My read

My take is simple:

• This is not a guaranteed winner.
• Medtech always has execution risk.
• NDA partnerships always create uncertainty until they are public.

But:

• The science is credible.
• The clinical signal is interesting.
• The commercial rollout is underway.
• The international footprint is expanding.
• The manufacturing setup looks real.
• The partner validation is unusually strong.

That combination is why I think this deserves more attention than it is getting.

Where to invest

Important:

Clyra Medical is not separately listed. The only way to invest is through the parent company.

I’m focusing this post on the medical product, clinical data, and commercial story, because that is the part that matters most to me right now.

• The way to invest is through $BLGO (OTQB)
• It is currently trading around $0.115 with around 330M shares outstanding
• That puts the market cap at below $40 million.
• BLGO owns 48% of Clyra and receives 6% royalties.
• So if Clyra keeps progressing, the current market may be pricing in far too little.

Final thought

The global wound care market is still searching for a better answer, and if ViaCLYR keeps delivering on the clinical side while commercial adoption and international rollout continue to build, this could end up looking absurdly cheap in hindsight.

At this low valuation, with the rest of the portfolio attached, I think it’s one of the most compelling asymmetric value/price setups worth a deep dive.

Disclaimer: This is my independent DD analysis of publicly available information and clinical presentations. Not financial advice.

https://preview.redd.it/v52sxmu75i7h1.png?width=1174&format=png&auto=webp&s=390456b23fe0e84aa735d846bd6a06e6b264cee8

I’ve been digging into Clyra Medical, and this is one of the cleanest small-cap medtech setups I’ve seen in a while. The combination of FDA clearance, real clinical presentation data, international distribution, and a major global partner still under strict NDA makes this feel like a story the market is not fully pricing in yet.

The setup

There’s a medical device company with:

• FDA-cleared product already in commercial launch.
• Real-world clinical presentation data.
• International distribution across the US, Europe, the Middle East, and North Africa.
• First commercial stocking order already shipped.
• A major global partner relationship still under strict NDA.
• Manufacturing capacity cited at around 2 million units per year.
• An implied valuation that still looks very small relative to the opportunity.

That is a lot of moving parts for a company the market is still treating like a tiny side story.

https://preview.redd.it/3irfm85dyh7h1.png?width=1688&format=png&auto=webp&s=ccf9f34ba73934b5909145bc31dcf45bc07becfe

https://preview.redd.it/vwbafcs8yh7h1.png?width=1906&format=png&auto=webp&s=538f9d3b064318120f48c7d7dfc00e5c5e629202

Why the science matters

ViaCLYR uses a copper-iodine complex designed to deliver broad-spectrum antimicrobial activity while remaining tissue-friendly and persistent enough to matter in real wound care.

What matters here is that this is not just about “killing bugs.” It is about the bigger chronic wound problem:

• biofilm,
• stalled healing,
• drainage,
• slough,
• tissue tolerance,
• and the practical limitations of current topicals.

THE CLYRA ADVANTAGE

ViaCLYR™ uses Copper-Iodine Complex Solution (CICS) technology designed to deliver broad-spectrum antimicrobial activity while remaining tissue-friendly and persistent enough to matter in real clinical workflows.

Medical advantages:

1.	No known resistance

• Copper-iodine complexes are attractive because they are not built on the same resistance-prone paradigm as antibiotics.
• That matters in chronic wound environments where repeated exposure can weaken many conventional approaches.

​

2.	Superior biofilm suppression

• Biofilm is one of the biggest reasons chronic wounds fail to heal.
• The Clyra thesis is that this technology can disrupt that barrier more effectively than standard options.

​

3.	Faster wound closure

• In the Boswick presentation, clinical experience was described as showing rapid wound transformation and enhanced healing.
• That is a strong signal if it continues to hold in broader clinical adoption.

​

4.	Sinus tract closure

• This is one of the harder wound complications to treat.
• The reported results suggest performance in areas where standard care often underperforms.

​

5.	No adverse reactions reported in the presented series

• That matters because a product can be antimicrobial and still be unusable if it irritates tissue or creates practical safety concerns.

​

6.	Real-world validation

• This was not presented as a theoretical concept.
• It was described in a multi-site, clinician-driven setting, which is more relevant than isolated lab claims.

The early clinical language from Boswick stood out to me immediately.

Quote callouts

>“Remarkable and unusual results.”

>“Rapid sinus tract closure.”

>“No adverse events in our treatment population.”

>“Adoption of CICS as our wound care cleansing modality of choice.”

That is not the tone of a weak product story.

https://preview.redd.it/1yswzayjyh7h1.png?width=970&format=png&auto=webp&s=d2cad8649f2b2b7bcf6b9c27e3f56e422050a83c

HOCl vs copper-iodine

One of the most interesting parts of the wound-care discussion is the comparison between HOCl and stoichiometric copper-iodine complexes like the Clyrasept technology used in ViaCLYR.

Why HOCl can be limiting

• It can be useful, but it is more finicky in practice.
• It is sensitive to light and oxygen.
• It can degrade faster than you would like.
• It may be less ideal for difficult chronic wounds where persistence matters.

Why copper-iodine is compelling

• It appears more stable at room temperature.
• It is better suited for predictable use and shelf life.
• It is designed to better penetrate mature biofilm.
• It may be more useful in slough-heavy, fibrotic, stalled wounds.

One clinician’s reaction really summed up the practical angle:

• Even without using HOCl personally, the biofilm penetration advantage looked meaningful.
• That seemed especially relevant in wounds with slough where sharp debridement is hard.
• If a product can work where conventional topicals are less practical, that is a real edge.

https://preview.redd.it/xot76espyh7h1.png?width=1956&format=png&auto=webp&s=d94a88ad6234949fe6f1dfeb4cc39f522a3c3e42

Clinical signal from Boswick

The Boswick presentation is one of the strongest validation points in the story.

https://preview.redd.it/b54wbu0z3i7h1.jpg?width=800&format=pjpg&auto=webp&s=1ff12e999522c46060c6b9dbfd5182da78abeba3

What was presented:

• Multi-site evaluation.
• Roughly 36 cases.
• Four wound clinics.
• Four-month period.
• Diabetic foot ulcers.
• Venous leg ulcers.
• Pressure injuries.
• Complex surgical wounds.

Reported outcomes:

• Very rapid reduction in wound fluid.
• Early increase in healing activity.
• Faster wound edge improvement.
• Rapid closure or shortening of wound tunnels.
• Dramatic wound transformation.
• No adverse events in the treatment group.

That is the kind of early clinical signal that makes both investors and clinicians pay attention.

https://preview.redd.it/ofb7ux4ezh7h1.png?width=1922&format=png&auto=webp&s=05c37581353052d12b5994d25b9ee12ecb5516bd

Commercial momentum

This is where the story starts to feel more real.

Management said:

• Clyra already shipped its first commercial stocking order.
• Two distributors are under contract.
• Distribution is being built in parallel with the regulatory rollout.
• Al Hikma is now part of the picture.
• Al Hikma covers the GCC, Levant, North Africa, and adjacent markets.
• That region represents more than 500 million people.

Why that matters:

• This is not just a science project.
• This is not just “coming soon.”
• This is a product moving into real channels.

https://preview.redd.it/a0tbn4u71i7h1.png?width=1712&format=png&auto=webp&s=f599723643a80a116aa9db80cf7849e8562f89fc

The “gorilla partner”

This may be the biggest validation point of all.

Management said:

• The major global partner is under strict NDA. A $100B+ company
• They are closer to the finish line than ever before.
• They completed a formative and summative human factors validation study.
• The final package is going to the FDA very soon.

Quote callouts

>“Closer to the finish line than we’ve ever been before.”

>“The final package is going to the FDA.”

>“Well-established, well networked, and credible with regulators.”

What I take from that:

• The company is in the late-stage packaging and validation phase.
• The partner is real enough to require confidentiality.
• The remaining work sounds procedural and regulatory, not conceptual.
• This is the kind of setup where people either lean in or miss it entirely.

https://preview.redd.it/6hmt2sp4zh7h1.png?width=1468&format=png&auto=webp&s=47c114eea369dc632935a906c31bf5f956ea8e0c

Manufacturing readiness

Another detail that matters:

• DD materials reference around 2 million units per year in manufacturing capacity.
• That suggests the company has already prepared for scale.
• That is much more credible than a “we’ll figure out production later” story.

Why that matters:

• If demand arrives, the product may already have a supply base ready.
• That lowers one of the biggest execution risks in small-cap medtech.
• It helps the commercial story feel more advanced than the market may be pricing in.

https://preview.redd.it/0aflenqyzh7h1.png?width=1226&format=png&auto=webp&s=75e0432ec89ba7b54c3f96209eafeaa8bcb2aaed

https://preview.redd.it/rujo6y6y1i7h1.png?width=1132&format=png&auto=webp&s=f1f1f817e05a05d564fbf3428b66169f6e938cf7

Why the valuation stands out

The simple case is this:

• FDA clearance.
• Clinical validation.
• Commercial stocking order.
• International distribution.
• NDA-protected major partner.
• Manufacturing readiness.

And yet the implied valuation still looks small relative to the setup.

The market may be:

• underestimating the rollout,
• missing the clinical significance,
• discounting the NDA partner because it is not public yet,
• or simply not paying attention.

https://preview.redd.it/vtg4p1ljzh7h1.png?width=1612&format=png&auto=webp&s=74211cbebe74e8fa462aea2e51733167b992d857

What you get for free

Here is the part that I think is being overlooked the most.

If you look at the parent company, the Clyra story is not the only thing you’re getting exposure to:

• AEC — water tech with real-world validation.
• Battery tech — long-duration storage optionality.
• Engineering business — a profitable engine with operating revenue.
• Odor elimination tech — the platform behind the blockbuster Pooph success.
• Clyra — the wound-care upside many people are focusing on now.

https://preview.redd.it/egx1mr6g3i7h1.png?width=1578&format=png&auto=webp&s=e4e047229707f1b27f516b0d2509ef7fe3a1c174

That is the kind of multi-asset setup that makes the current valuation feel detached from the sum of the parts.

My read

My take is simple:

• This is not a guaranteed winner.
• Medtech always has execution risk.
• NDA partnerships always create uncertainty until they are public.

But:

• The science is credible.
• The clinical signal is interesting.
• The commercial rollout is underway.
• The international footprint is expanding.
• The manufacturing setup looks real.
• The partner validation is unusually strong.

That combination is why I think this deserves more attention than it is getting.

Where to invest

Important:

Clyra Medical is not separately listed. The only way to invest is through the parent company.

I’m focusing this post on the medical product, clinical data, and commercial story, because that is the part that matters most to me right now.

• The way to invest is through $BLGO (OTQB)
• It is currently trading around $0.115 with around 330M shares outstanding
• That puts the market cap at below $40 million.
• BLGO owns 48% of Clyra and receives 6% royalties.
• So if Clyra keeps progressing, the current market may be pricing in far too little.

Final thought

The global wound care market is still searching for a better answer, and if ViaCLYR keeps delivering on the clinical side while commercial adoption and international rollout continue to build, this could end up looking absurdly cheap in hindsight.

At this low valuation, with the rest of the portfolio attached, I think it’s one of the most compelling asymmetric value/price setups worth a deep dive.

Disclaimer: This is my independent DD analysis of publicly available information and clinical presentations. Not financial advice.

BioLargo is an environmental technology company dedicated to delivering innovative solutions for clean air, clean water, and a healthier planet.

After a string of real, value-generating milestones over the last ~120 days, it’s honestly hard to justify a sub-$50M valuation here.

I consider 5–7x returns very likely, and more than 20x returns entirely possible. If they deliver on most fronts, even 50–87x could become a reality.

So this barely qualifies here ;)

This isn’t hype — it’s execution:

✅ Lake Stockholm AEC install (Jan 27, 2026) — live, in-ground, under NJDEP ; EPA oversight. First real municipal PFAS deployment.

✅ Clyra first stocking order (Feb 2026) — secured via Advanced Solutions’ national distribution. Hospitals and clinics. Revenue underway.

✅ Al Hikma deal (May 5, 2026) — exclusive MENA distribution for ViaCLYR™ across GCC and Levant markets.

✅ $1.2M Minerals contract (Apr 20, 2026) — BioLargo Engineering leading pilot-scale facility design.

✅ Aquatech MOU (May 3, 2026) — another AEC partnership advancing.

On top of that: revenues rebounding with 81% QoQ growth off Q4 lows.

Price is what you pay. Value is what you get.

And right now, the gap between the two is hard to ignore.

For better understanding- Read my full DD - made for some German family members here (safe link)

https://drive.google.com/file/d/1kdLS5k6SavYx6xNh85ww9vg2unC4JP0y/view?usp=drivesdk

English version:

https://drive.google.com/file/d/133fUlR-Mu\_SXFzdthMuSeE\_7ZPPkm1\_q/view?usp=drivesdk

$BLGO 50% Up from recent lows and still massively undervalued.

After a string of real, value-generating milestones over the last ~120 days, it’s honestly hard to justify a sub-$50M valuation here.

This isn’t hype — it’s execution:

✅ Lake Stockholm AEC install (Jan 27, 2026) — live, in-ground, under NJDEP ; EPA oversight. First real municipal PFAS deployment.

✅ Clyra first stocking order (Feb 2026) — secured via Advanced Solutions’ national distribution. Hospitals and clinics. Revenue underway.

✅ Al Hikma deal (May 5, 2026) — exclusive MENA distribution for ViaCLYR™ across GCC and Levant markets.

✅ $1.2M Minerals contract (Apr 20, 2026) — BioLargo Engineering leading pilot-scale facility design.

✅ Aquatech MOU (May 3, 2026) — another AEC partnership advancing.

On top of that: revenues rebounding with 81% QoQ growth off Q4 lows.

Price is what you pay. Value is what you get.

And right now, the gap between the two is hard to ignore.

For better understanding- Read my full DD - made for some family members here:

https://drive.google.com/file/d/133fUlR-Mu\_SXFzdthMuSeE\_7ZPPkm1\_q/view

$BLGO 50% Up from recent lows and still massively undervalued.

After a string of real, value-generating milestones over the last \~120 days, it’s honestly hard to justify a sub-$50M valuation here.

This isn’t hype — it’s execution:

✅ Lake Stockholm AEC install (Jan 27, 2026) — live, in-ground, under NJDEP \& EPA oversight. First real municipal PFAS deployment.

✅ Clyra first stocking order (Feb 2026) — secured via Advanced Solutions’ national distribution. Hospitals and clinics. Revenue underway.

✅ Al Hikma deal (May 5, 2026) — exclusive MENA distribution for ViaCLYR™ across GCC and Levant markets.

✅ $1.2M Minerals contract (Apr 20, 2026) — BioLargo Engineering leading pilot-scale facility design.

✅ Aquatech MOU (May 3, 2026) — another AEC partnership advancing.

On top of that: revenues rebounding with 81% QoQ growth off Q4 lows.

Price is what you pay. Value is what you get.

And right now, the gap between the two is hard to ignore.

For better understanding- Read my full DD - made for some family members here:

https://drive.google.com/file/d/133fUlR-Mu\\\_SXFzdthMuSeE\\\_7ZPPkm1\\\_q/view

TL;DR: This is my personal take, written for my brother-in-law and his uncle, a retired doctor, after a recent family gathering turned into a deep conversation about why I remain so heavily invested in BioLargo.

I know many people disagree with me, but I’ve seen before how the best opportunities often look the worst before they work.

A recent family gathering turned into one of those conversations that stays with you. My brother-in-law and his uncle, who is a retired doctor, were genuinely curious why I would keep investing in BioLargo while the share price is under pressure and sentiment remains so low. It was a fair question, and honestly, exactly the kind of question I welcome.

This is my personal take, written for them to explain my thinking clearly and honestly. And as a doctor, he can put the Clyra Medical Clyrasept platform into perspective, especially when it comes to the importance of finding the best possible partners.

I recently added another $40,000 to my position, and I now own about 1.25% of BioLargo. That kind of conviction does not come from hype - it comes from years of doing the work, accepting criticism, and being willing to look wrong before the market eventually proves you right.

I’ve seen this story before.

When I invested in Exact Sciences, people told me I was making a mistake. The sentiment was terrible, the stock was under pressure, and the criticism was loud. But I stayed with it because I believed in the story and the science, and that decision eventually turned into more than 2000% gains. Experiences like that shape how you see opportunity. More detail about it in the post.

It also matters where you invest.

For me, this has never been only about making money. I want to back companies that are trying to solve real problems and create something meaningful. Clean Water, Clean Air, a change in wound care, lithium free batteries. Yes please!

That is what makes investing more than a numbers game - it becomes a way of supporting technologies and businesses that actually matter, especially when they have the potential to improve lives, solve hard problems, or build something lasting.

That purpose is a big part of why I stay patient when others lose interest.

That is why I am not afraid of criticism around BioLargo. In fact, I expect it. I understand why people are skeptical. But in my view, that skepticism is exactly what often creates the most interesting investment setups.

The best opportunities are rarely comfortable. They usually look unpopular, misunderstood, and even irrational before they start to work.

So this is not me asking anyone to blindly agree. It is simply my personal long-term view, written for family, and shared here for anyone who wants to read the deeper thesis.

Too long; didn’t read?

I wrote this for my brother-in-law and his retired-doctor uncle after a family discussion, and my view is still the same:

BioLargo is misunderstood, I recently added another $40,000, and I’m willing to be early again because I’ve seen what conviction can do when the crowd is wrong.

Download the full DD here:

https://drive.google.com/file/d/133fUlR-Mu\\\_SXFzdthMuSeE\\\_7ZPPkm1\\\_q/view

TL;DR: This is my personal take, written for my brother-in-law and his uncle, a retired doctor, after a recent family gathering turned into a deep conversation about why I remain so heavily invested in BioLargo.

I know many people disagree with me, but I’ve seen before how the best opportunities often look the worst before they work.

A recent family gathering turned into one of those conversations that stays with you. My brother-in-law and his uncle, who is a retired doctor, were genuinely curious why I would keep investing in BioLargo while the share price is under pressure and sentiment remains so low. It was a fair question, and honestly, exactly the kind of question I welcome.

This is my personal take, written for them to explain my thinking clearly and honestly. And as a doctor, he can put the Clyra Medical Clyrasept platform into perspective, especially when it comes to the importance of finding the best possible partners.

I recently added another $40,000 to my position, and I now own about 1.25% of BioLargo. That kind of conviction does not come from hype - it comes from years of doing the work, accepting criticism, and being willing to look wrong before the market eventually proves you right.

I’ve seen this story before.

When I invested in Exact Sciences, people told me I was making a mistake. The sentiment was terrible, the stock was under pressure, and the criticism was loud. But I stayed with it because I believed in the story and the science, and that decision eventually turned into more than 2000% gains. Experiences like that shape how you see opportunity. More detail about it in the post.

It also matters where you invest.

For me, this has never been only about making money. I want to back companies that are trying to solve real problems and create something meaningful. Clean Water, Clean Air, a change in wound care, lithium free batteries. Yes please!

That is what makes investing more than a numbers game - it becomes a way of supporting technologies and businesses that actually matter, especially when they have the potential to improve lives, solve hard problems, or build something lasting.

That purpose is a big part of why I stay patient when others lose interest.

That is why I am not afraid of criticism around BioLargo. In fact, I expect it. I understand why people are skeptical. But in my view, that skepticism is exactly what often creates the most interesting investment setups.

The best opportunities are rarely comfortable. They usually look unpopular, misunderstood, and even irrational before they start to work.

So this is not me asking anyone to blindly agree. It is simply my personal long-term view, written for family, and shared here for anyone who wants to read the deeper thesis.

Too long; didn’t read?

I wrote this for my brother-in-law and his retired-doctor uncle after a family discussion, and my view is still the same:

BioLargo is misunderstood, I recently added another $40,000, and I’m willing to be early again because I’ve seen what conviction can do when the crowd is wrong.

Download the full DD here:

https://drive.google.com/file/d/133fUlR-Mu\_SXFzdthMuSeE\_7ZPPkm1\_q/view

TL;DR: This is my personal take, written for my brother-in-law and his uncle, a retired doctor, after a recent family gathering turned into a deep conversation about why I remain so heavily invested in BioLargo.

I know many people disagree with me, but I’ve seen before how the best opportunities often look the worst before they work.

A recent family gathering turned into one of those conversations that stays with you. My brother-in-law and his uncle, who is a retired doctor, were genuinely curious why I would keep investing in BioLargo while the share price is under pressure and sentiment remains so low. It was a fair question, and honestly, exactly the kind of question I welcome.

This is my personal take, written for them to explain my thinking clearly and honestly. And as a doctor, he can put the Clyra Medical Clyrasept platform into perspective, especially when it comes to the importance of finding the best possible partners.

I recently added another $40,000 to my position, and I now own about 1.25% of BioLargo. That kind of conviction does not come from hype - it comes from years of doing the work, accepting criticism, and being willing to look wrong before the market eventually proves you right.

I’ve seen this story before.

When I invested in Exact Sciences, people told me I was making a mistake. The sentiment was terrible, the stock was under pressure, and the criticism was loud. But I stayed with it because I believed in the story and the science, and that decision eventually turned into more than 2000% gains. Experiences like that shape how you see opportunity. More detail about it in the post.

It also matters where you invest.

For me, this has never been only about making money. I want to back companies that are trying to solve real problems and create something meaningful. Clean Water, Clean Air, a change in wound care, lithium free batteries. Yes please!

That is what makes investing more than a numbers game - it becomes a way of supporting technologies and businesses that actually matter, especially when they have the potential to improve lives, solve hard problems, or build something lasting.

That purpose is a big part of why I stay patient when others lose interest.

That is why I am not afraid of criticism around BioLargo. In fact, I expect it. I understand why people are skeptical. But in my view, that skepticism is exactly what often creates the most interesting investment setups.

The best opportunities are rarely comfortable. They usually look unpopular, misunderstood, and even irrational before they start to work.

So this is not me asking anyone to blindly agree. It is simply my personal long-term view, written for family, and shared here for anyone who wants to read the deeper thesis.

Too long; didn’t read?

I wrote this for my brother-in-law and his retired-doctor uncle after a family discussion, and my view is still the same:

BioLargo is misunderstood, I recently added another $40,000, and I’m willing to be early again because I’ve seen what conviction can do when the crowd is wrong.

Download the full DD here:

https://drive.google.com/file/d/133fUlR-Mu\_SXFzdthMuSeE\_7ZPPkm1\_q/view

TL;DR: This is my personal take, written for my brother-in-law and his uncle, a retired doctor, after a recent family gathering turned into a deep conversation about why I remain so heavily invested in BioLargo.

I know many people disagree with me, but I’ve seen before how the best opportunities often look the worst before they work.

A recent family gathering turned into one of those conversations that stays with you. My brother-in-law and his uncle, who is a retired doctor, were genuinely curious why I would keep investing in BioLargo while the share price is under pressure and sentiment remains so low. It was a fair question, and honestly, exactly the kind of question I welcome.

This is my personal take, written for them to explain my thinking clearly and honestly. And as a doctor, he can put the Clyra Medical Clyrasept platform into perspective, especially when it comes to the importance of finding the best possible partners.

I recently added another $40,000 to my position, and I now own about 1.25% of BioLargo. That kind of conviction does not come from hype - it comes from years of doing the work, accepting criticism, and being willing to look wrong before the market eventually proves you right.

I’ve seen this story before.

When I invested in Exact Sciences, people told me I was making a mistake. The sentiment was terrible, the stock was under pressure, and the criticism was loud. But I stayed with it because I believed in the story and the science, and that decision eventually turned into more than 2000% gains. Experiences like that shape how you see opportunity. More detail about it in the post.

It also matters where you invest.

For me, this has never been only about making money. I want to back companies that are trying to solve real problems and create something meaningful. Clean Water, Clean Air, a change in wound care, lithium free batteries. Yes please!

That is what makes investing more than a numbers game - it becomes a way of supporting technologies and businesses that actually matter, especially when they have the potential to improve lives, solve hard problems, or build something lasting.

That purpose is a big part of why I stay patient when others lose interest.

That is why I am not afraid of criticism around BioLargo. In fact, I expect it. I understand why people are skeptical. But in my view, that skepticism is exactly what often creates the most interesting investment setups.

The best opportunities are rarely comfortable. They usually look unpopular, misunderstood, and even irrational before they start to work.

So this is not me asking anyone to blindly agree. It is simply my personal long-term view, written for family, and shared here for anyone who wants to read the deeper thesis.

Too long; didn’t read?

I wrote this for my brother-in-law and his retired-doctor uncle after a family discussion, and my view is still the same:

BioLargo is misunderstood, I recently added another $40,000, and I’m willing to be early again because I’ve seen what conviction can do when the crowd is wrong.

Download the full DD here:

https://drive.google.com/file/d/133fUlR-Mu\_SXFzdthMuSeE\_7ZPPkm1\_q/view

I’m happy to share the English version of my BioLargo DD, which I first created for my German family members that got very curious about my investment into this purposeful company on a recent gathering. Fellow BioLargo investors - please let me know your thoughts. I’m very open to feedback, improvements, and pushback, and I’d love to discuss any points you agree or disagree with:

Download File Here:

https://drive.google.com/file/d/133fUlR-Mu\_SXFzdthMuSeE\_7ZPPkm1\_q/view?usp=drivesdk

https://discord.com/channels/838045954589327373/838045955348889652/1512091782207242290

🤯 A Company With 4 Revenue-Generating Subsidiaries Trading at This $35 Million Market Cap Is Absurd. BioLargo $BLGO

💥 Yes, I put my money where my mouth is. I trust my DD - just added heavily in this region. 🎯

I’ve been here before. Different ticker, same setup. EXAS went 2,000% from where I bought on a crazy dip - I’m seeing the same pattern in $BLGO and I just added heavily.

Let’s be real about what just happened. Someone exited their position, fear cascaded, and retail panic did what it always does - handed shares from weak hands to strong ones. If you’ve been following BioLargo for any length of time, you’ve seen this movie before. And you know how it ends.

The fundamentals have not changed. Not even slightly. What HAS changed is the price - and that means the opportunity just got bigger.

\---

The Market Cap Argument Is Absurd

Let’s put this in perspective. A 10X move from here represents a market cap of only \~$350 million dollars. For context, that is a rounding error for most mid-cap cleantech companies. BioLargo is not a shell, not a concept, not a whitepaper. It is a multi-subsidiary operating company with real contracts, real revenue, real technology, and real momentum across multiple verticals simultaneously.

The market simply hasn’t caught up yet. That’s the opportunity.

\---

What’s Actually Happening Inside This Company Right Now

💧 AEC PFAS Water Treatment - The Crown Jewel

BioLargo’s Aqueous Electrostatic Concentrator (AEC) has been installed at a real municipal drinking water facility in Lake Stockholm, NJ. This isn’t a lab demo - it’s boots on the ground, treating real water for real communities. On top of that, the team achieved a greater than 90% reduction in energy use, which is the single biggest barrier to PFAS treatment scalability. The technology was featured in Chemical Engineering magazine. Aquatech - a globally recognized water technology company - signed an MOU with BioLargo to accelerate PFAS commercialization. The regulatory tailwind from EPA PFAS drinking water standards is enormous and only getting stronger.

🏭 BioLargo Engineering, Science & Technologies (BEST) - Revenue Engine

BEST is not waiting around. A $1.2 million contract was awarded in April 2026 to design a pilot-scale minerals processing facility. Engineering services revenue grew +98% in 2025. This subsidiary is profitable, cash-generating, and feeds directly into the broader IP commercialization pipeline. It also gives BioLargo operational credibility that pure-play IP companies simply don’t have.

🩹 Clyra Medical - MENA Expansion Underway

Clyra secured an exclusive distribution agreement for ViaCLYR™ across the Middle East and North Africa. This is a meaningful geographic expansion for a wound care product with demonstrated clinical efficacy. 2026 was flagged as a year of meaningful revenue contribution from Clyra — and the distribution deal puts that squarely in play.

🔋 BioLargo Energy — Battery JV in Motion

The battery technology joint venture is advancing toward commercialization. Energy storage is one of the hottest sectors on the planet right now. BioLargo has a seat at that table too.

\---

The Big Picture

This is a company operating across PFAS water treatment, wound care, environmental engineering, and energy storage — four sectors with massive tailwinds, growing regulatory support, and surging institutional interest globally. The CEO has been transparent, the team has been executing, and the catalysts keep stacking.

Weak hands just gave you their shares. The question is whether you’re going to take them.

Do your own DD. Read the filings. Watch the CEO interviews. Understand what you own.

But if you’ve done that work already — you know what this is.

🙏 Not financial advice. Do your own due diligence.

\#BLGO #BioLargo #cleantech #PFAS #watertreatment #undervalued #smallcap #investing

Let’s be real about what just happened. Someone exited their position, fear cascaded, and retail panic did what it always does - handed shares from weak hands to strong ones. If you’ve been following BioLargo for any length of time, you’ve seen this movie before. And you know how it ends.

The fundamentals have not changed. Not even slightly. What HAS changed is the price - and that means the opportunity just got bigger.

---

The Market Cap Argument Is Absurd

Let’s put this in perspective. A 10X move from here represents a market cap of only ~$350 million dollars. For context, that is a rounding error for most mid-cap cleantech companies. BioLargo is not a shell, not a concept, not a whitepaper. It is a multi-subsidiary operating company with real contracts, real revenue, real technology, and real momentum across multiple verticals simultaneously.

The market simply hasn’t caught up yet. That’s the opportunity.

---

What’s Actually Happening Inside This Company Right Now

💧 AEC PFAS Water Treatment - The Crown Jewel

BioLargo’s Aqueous Electrostatic Concentrator (AEC) has been installed at a real municipal drinking water facility in Lake Stockholm, NJ. This isn’t a lab demo - it’s boots on the ground, treating real water for real communities. On top of that, the team achieved a greater than 90% reduction in energy use, which is the single biggest barrier to PFAS treatment scalability. The technology was featured in Chemical Engineering magazine. Aquatech - a globally recognized water technology company - signed an MOU with BioLargo to accelerate PFAS commercialization. The regulatory tailwind from EPA PFAS drinking water standards is enormous and only getting stronger.

🏭 BioLargo Engineering, Science & Technologies (BEST) - Revenue Engine

BEST is not waiting around. A $1.2 million contract was awarded in April 2026 to design a pilot-scale minerals processing facility. Engineering services revenue grew +98% in 2025. This subsidiary is profitable, cash-generating, and feeds directly into the broader IP commercialization pipeline. It also gives BioLargo operational credibility that pure-play IP companies simply don’t have.

🩹 Clyra Medical - MENA Expansion Underway

Clyra secured an exclusive distribution agreement for ViaCLYR™ across the Middle East and North Africa. This is a meaningful geographic expansion for a wound care product with demonstrated clinical efficacy. 2026 was flagged as a year of meaningful revenue contribution from Clyra — and the distribution deal puts that squarely in play.

🔋 BioLargo Energy — Battery JV in Motion

The battery technology joint venture is advancing toward commercialization. Energy storage is one of the hottest sectors on the planet right now. BioLargo has a seat at that table too.

---

The Big Picture

This is a company operating across PFAS water treatment, wound care, environmental engineering, and energy storage — four sectors with massive tailwinds, growing regulatory support, and surging institutional interest globally. The CEO has been transparent, the team has been executing, and the catalysts keep stacking.

Weak hands just gave you their shares. The question is whether you’re going to take them.

Do your own DD. Read the filings. Watch the CEO interviews. Understand what you own.

But if you’ve done that work already — you know what this is.

🙏 Not financial advice. Do your own due diligence.

#BLGO #BioLargo #cleantech #PFAS #watertreatment #undervalued #smallcap #investing

Our treasure chest is filled with inspiring young companies that have innovative solutions to address a clean, low-carbon environment and to provide disruptive technologies to make life better

TOMORROW'S WINNERS TODAY

There are moments in the small-cap world when a company quietly assembles so many high-potential businesses, technologies, partnerships, and commercial opportunities that the market simply cannot ignore it forever. Investors spend years searching for companies with one breakthrough catalyst. BioLargo may now have several unfolding at the same time.

​

For years, many investors viewed BioLargo (BLGO: OTCQX) as a fascinating technology incubator with enormous promise but waiting for large-scale commercialization. That narrative appears to be changing rapidly. Today, the company is no longer just developing technology - it is signing contracts, building strategic partnerships, entering billion-dollar markets, and positioning itself for what could become a transformational growth phase.

The opportunity may still be flying under Wall Street’s radar.

At the center of the excitement is BioLargo’s CLYRA technology and what appears to be a potentially game-changing signed agreement with a major global player. Investors understand what happens when a small technology company secures validation from a major industrial or multinational organization. It can dramatically accelerate credibility, adoption, revenue opportunities, and investor attention almost overnight.

BIOLARGO addresses one of the world’s biggest emerging environmental and infrastructure problems: advanced water treatment and contaminant removal. Governments, municipalities, industrial operators, and military installations are under increasing pressure to remove toxic compounds from water systems safely and economically. The global urgency surrounding PFAS contamination alone is staggering.

PFAS chemicals - often called “forever chemicals” - have become one of the largest environmental remediation markets in the world.

Regulatory pressure is increasing, lawsuits are expanding, and companies everywhere are searching for workable solutions. BioLargo is entering this market at exactly the right time.

What makes the BioLargo story particularly compelling is that the company reportedly has approximately $200 million worth of PFAS-related requests for proposals in its pipeline. That number alone has the potential to reshape investor perception of the company if even a portion converts into signed business.

The market often rewards potential before revenues fully materialize. Investors know that once major contracts begin stacking up, share prices can move quickly as institutions and speculative capital rush to gain exposure ahead of broader commercialization.

And BioLargo is not approaching this market alone.

Its partnership with Aquatech could prove to be one of the most important strategic relationships in the company’s history. Aquatech is a recognized global player in water purification and industrial treatment solutions. Partnerships like this do not happen by accident. Large established organizations conduct extensive technical reviews before aligning themselves with emerging technologies.

That partnership may signal confidence that BioLargo’s solutions are scalable, commercially viable, and capable of competing in enormous international markets.

Then there is the Cellinity battery.

Many investors believe Cellinity may eventually become one of the crown jewels inside BioLargo’s portfolio. The battery and energy storage sector has become one of the most competitive and strategically important industries in the world. Yet despite billions of dollars being invested across the sector, many technologies continue to struggle with cost, safety, environmental concerns, and performance limitations.

Cellinity appears to offer a differentiated approach that some believe could disrupt portions of the energy storage market. If the technology performs at commercial scale the way supporters believe it can, BioLargo may possess an undervalued asset with applications across multiple industries, including grid storage, industrial systems, and renewable energy infrastructure.

Most small companies would be fortunate to have one major growth driver. **BioLargo appears to have several operating simultaneously.**

Then there is Pooph.

Many investors may remember the explosive consumer success and viral growth surrounding the Pooph odor elimination brand. The product generated substantial consumer awareness and demonstrated BioLargo’s ability to develop commercially successful consumer technologies in addition to industrial solutions.

Now investors are increasingly discussing the possibility of a Pooph revival and expansion. Consumer products with strong brand recognition can become enormously valuable recurring revenue businesses, especially when supported by retail expansion, e-commerce growth, and licensing opportunities.

Importantly, Pooph also demonstrated impressive sales and something many speculative technology companies never prove: BioLargo can create products people actually buy in large quantities.

Beyond water treatment, energy storage, and consumer products, BioLargo also has exposure to mining-related opportunities and additional environmental technologies that could create future value. The company’s diversified portfolio gives investors multiple “shots on goal,” reducing reliance on any single catalyst.

What may make this moment especially unusual is the convergence of timing.

Environmental regulations are tightening globally. PFAS remediation spending is accelerating. Infrastructure modernization is becoming a national priority. Energy storage demand continues to expand worldwide. Strategic partnerships are forming. Contracts are being signed. Commercial validation appears to be increasing.

And perhaps most importantly for investors, BioLargo’s valuation may still not fully reflect the magnitude of these opportunities.

The market often waits until revenue growth becomes undeniable before repricing a company. By then, many of the largest gains have already occurred. Some investors believe BioLargo may currently represent one of those rare asymmetrical opportunities where downside appears limited relative to the scale of potential upside if commercialization accelerates.

The company has already secured significant contracts with major users, further validating that large organizations are willing to deploy BioLargo technologies in real-world applications. Investors are also anticipating the possibility of additional major agreements in the near future. If more large contracts are announced soon, market attention could intensify rapidly.

Small-cap investing is never without risk. Execution, financing, commercialization speed, and market conditions all matter. But rare opportunities occasionally emerge where multiple megatrends intersect within one overlooked company.

BioLargo appears to be positioning itself directly at the intersection of clean water, environmental remediation, advanced energy storage, infrastructure modernization, and consumer product innovation.

That combination is exceptionally rare.

If even a fraction of the company’s pipeline, partnerships, and technologies reach their commercial potential, today’s valuation could eventually look remarkably small in hindsight. For investors searching for an emerging company with multiple transformational catalysts already in motion, BioLargo may deserve very close attention.

Our treasure chest is filled with inspiring young companies that have innovative solutions to address a clean, low-carbon environment and to provide disruptive technologies to make life better

​

TOMORROW'S WINNERS TODAY

There are moments in the small-cap world when a company quietly assembles so many high-potential businesses, technologies, partnerships, and commercial opportunities that the market simply cannot ignore it forever. Investors spend years searching for companies with one breakthrough catalyst. BioLargo may now have several unfolding at the same time.

​

For years, many investors viewed BioLargo (BLGO: OTCQX) as a fascinating technology incubator with enormous promise but waiting for large-scale commercialization. That narrative appears to be changing rapidly. Today, the company is no longer just developing technology - it is signing contracts, building strategic partnerships, entering billion-dollar markets, and positioning itself for what could become a transformational growth phase.

​

The opportunity may still be flying under Wall Street’s radar.

​

At the center of the excitement is BioLargo’s CLYRA technology and what appears to be a potentially game-changing signed agreement with a major global player. Investors understand what happens when a small technology company secures validation from a major industrial or multinational organization. It can dramatically accelerate credibility, adoption, revenue opportunities, and investor attention almost overnight.

​

BIOLARGO addresses one of the world’s biggest emerging environmental and infrastructure problems: advanced water treatment and contaminant removal. Governments, municipalities, industrial operators, and military installations are under increasing pressure to remove toxic compounds from water systems safely and economically. The global urgency surrounding PFAS contamination alone is staggering.

PFAS chemicals - often called “forever chemicals” - have become one of the largest environmental remediation markets in the world.

Regulatory pressure is increasing, lawsuits are expanding, and companies everywhere are searching for workable solutions. BioLargo is entering this market at exactly the right time.

​

What makes the BioLargo story particularly compelling is that the company reportedly has approximately $200 million worth of PFAS-related requests for proposals in its pipeline. That number alone has the potential to reshape investor perception of the company if even a portion converts into signed business.

​

The market often rewards potential before revenues fully materialize. Investors know that once major contracts begin stacking up, share prices can move quickly as institutions and speculative capital rush to gain exposure ahead of broader commercialization.

​

And BioLargo is not approaching this market alone.

​

Its partnership with Aquatech could prove to be one of the most important strategic relationships in the company’s history. Aquatech is a recognized global player in water purification and industrial treatment solutions. Partnerships like this do not happen by accident. Large established organizations conduct extensive technical reviews before aligning themselves with emerging technologies.

​

That partnership may signal confidence that BioLargo’s solutions are scalable, commercially viable, and capable of competing in enormous international markets.

​

Then there is the Cellinity battery.

​

Many investors believe Cellinity may eventually become one of the crown jewels inside BioLargo’s portfolio. The battery and energy storage sector has become one of the most competitive and strategically important industries in the world. Yet despite billions of dollars being invested across the sector, many technologies continue to struggle with cost, safety, environmental concerns, and performance limitations.

​

Cellinity appears to offer a differentiated approach that some believe could disrupt portions of the energy storage market. If the technology performs at commercial scale the way supporters believe it can, BioLargo may possess an undervalued asset with applications across multiple industries, including grid storage, industrial systems, and renewable energy infrastructure.

​

Most small companies would be fortunate to have one major growth driver. BioLargo appears to have several operating simultaneously.

Then there is Pooph.

​

Many investors may remember the explosive consumer success and viral growth surrounding the Pooph odor elimination brand. The product generated substantial consumer awareness and demonstrated BioLargo’s ability to develop commercially successful consumer technologies in addition to industrial solutions.

​

Now investors are increasingly discussing the possibility of a Pooph revival and expansion. Consumer products with strong brand recognition can become enormously valuable recurring revenue businesses, especially when supported by retail expansion, e-commerce growth, and licensing opportunities.

​

Importantly, Pooph also demonstrated impressive sales and something many speculative technology companies never prove: BioLargo can create products people actually buy in large quantities.

​

Beyond water treatment, energy storage, and consumer products, BioLargo also has exposure to mining-related opportunities and additional environmental technologies that could create future value. The company’s diversified portfolio gives investors multiple “shots on goal,” reducing reliance on any single catalyst.

​

What may make this moment especially unusual is the convergence of timing.

​

Environmental regulations are tightening globally. PFAS remediation spending is accelerating. Infrastructure modernization is becoming a national priority. Energy storage demand continues to expand worldwide. Strategic partnerships are forming. Contracts are being signed. Commercial validation appears to be increasing.

​

And perhaps most importantly for investors, BioLargo’s valuation may still not fully reflect the magnitude of these opportunities.

​

The market often waits until revenue growth becomes undeniable before repricing a company. By then, many of the largest gains have already occurred. Some investors believe BioLargo may currently represent one of those rare asymmetrical opportunities where downside appears limited relative to the scale of potential upside if commercialization accelerates.

​

The company has already secured significant contracts with major users, further validating that large organizations are willing to deploy BioLargo technologies in real-world applications. Investors are also anticipating the possibility of additional major agreements in the near future. If more large contracts are announced soon, market attention could intensify rapidly.

​

Small-cap investing is never without risk. Execution, financing, commercialization speed, and market conditions all matter. But rare opportunities occasionally emerge where multiple megatrends intersect within one overlooked company.

​

BioLargo appears to be positioning itself directly at the intersection of clean water, environmental remediation, advanced energy storage, infrastructure modernization, and consumer product innovation.

​

That combination is exceptionally rare.

If even a fraction of the company’s pipeline, partnerships, and technologies reach their commercial potential, today’s valuation could eventually look remarkably small in hindsight. For investors searching for an emerging company with multiple transformational catalysts already in motion, BioLargo may deserve very close attention.

Strategic Partnership Aims to Scale Advanced “Forever Chemicals” Remediation Solutions for Safer Water and Environmental Protection.

By Henry DeVries, Senior Writer, California Business Journal

Southern California cleantech company BioLargo and global water purification company Aquatech are collaborating to enable the deployment of technology as a concentration and collection step within Aquatech’s full flowsheet solutions for PFAS treatment, including destruction.

“By partnering with Aquatech – one of the most respected and capable organizations in the global water treatment industry – we can significantly amplify the reach and impact of our Aqueous Electrostatic Concentrator technology,” said Tonya Chandler, president of BioLargo Equipment. “Together, we are combining proven engineering, innovative science, and deep market experience to deliver scalable PFAS treatment solutions for industrial, municipal, and government clients.”

BioLargo Equipment is a subsidiary of BioLargo, Inc. (OTCQX:BLGO), an environmental engineering company developing and commercializing sustainable technologies, announced it has signed into a memorandum of understanding (MOU) with Aquatech to advance the integration and commercialization of BioLargo’s proprietary Aqueous Electrostatic Concentrator (AEC) for PFAS treatment.

BioLargo’s AEC technology is designed to remove per- and polyfluoroalkyl substances (PFAS) from liquid streams, producing treated water suitable for drinking water applications. AEC uses electromotive force to collect and immobilize PFAS directly onto membrane surfaces without generating a secondary concentrated liquid waste stream.

This collaboration enhances the two companies’ ability to integrate AEC with Aquatech’s comprehensive, end-to-end PFAS treatment solutions that enable their public and private sector clients to meet evolving regulatory requirements.

Aquatech is globally recognized for its technical excellence and innovation in sustainable water and wastewater management and was awarded Water Technology Company of the Year at the 2025 Global Water Summit in Paris, France. Aquatech’s industry-leading technology portfolio includes membrane, thermal, biological, electrochemical and ultrapure water treatment solutions.

The agreement establishes a non-exclusive framework for collaboration on PFAS treatment projects worldwide, enabling both companies to combine their complementary technologies to better serve the rapidly growing PFAS remediation market.

Aquatech International’s corporate headquarters is located in Canonsburg, Pennsylvania, Established in 1981, the company is a global leader in water purification technology for industrial and infrastructure markets, specializing in desalination, water reuse, and zero liquid discharge.

“Coupling BioLargo’s AEC PFAS collection and concentration technology with Aquatech’s PFAS removal and destruction expertise presents a powerful opportunity to fast-track effective solutions to serve the customer,” said Devesh Mittal, vice president of Aquatech Environmental Services.

Henry DeVries is a former Forbes online columnist who is the chief book strategist at Indie Books International. He has ghostwritten, co-authored, or edited more than 200 business books, including his international bestseller, How to Close a Deal Like Warren Buffett*.*

https://calbizjournal.com/biolargo-signs-deal-to-accelerate-commercialization-of-pfas-treatment-technology/

Strategic Partnership Aims to Scale Advanced “Forever Chemicals” Remediation Solutions for Safer Water and Environmental Protection.

By Henry DeVries, Senior Writer, California Business Journal

Southern California cleantech company BioLargo and global water purification company Aquatech are collaborating to enable the deployment of technology as a concentration and collection step within Aquatech’s full flowsheet solutions for PFAS treatment, including destruction.

“By partnering with Aquatech – one of the most respected and capable organizations in the global water treatment industry – we can significantly amplify the reach and impact of our Aqueous Electrostatic Concentrator technology,” said Tonya Chandler, president of BioLargo Equipment. “Together, we are combining proven engineering, innovative science, and deep market experience to deliver scalable PFAS treatment solutions for industrial, municipal, and government clients.”

BioLargo Equipment is a subsidiary of BioLargo, Inc. (OTCQX:BLGO), an environmental engineering company developing and commercializing sustainable technologies, announced it has signed into a memorandum of understanding (MOU) with Aquatech to advance the integration and commercialization of BioLargo’s proprietary Aqueous Electrostatic Concentrator (AEC) for PFAS treatment.

BioLargo’s AEC technology is designed to remove per- and polyfluoroalkyl substances (PFAS) from liquid streams, producing treated water suitable for drinking water applications. AEC uses electromotive force to collect and immobilize PFAS directly onto membrane surfaces without generating a secondary concentrated liquid waste stream.

This collaboration enhances the two companies’ ability to integrate AEC with Aquatech’s comprehensive, end-to-end PFAS treatment solutions that enable their public and private sector clients to meet evolving regulatory requirements.

Aquatech is globally recognized for its technical excellence and innovation in sustainable water and wastewater management and was awarded Water Technology Company of the Year at the 2025 Global Water Summit in Paris, France. Aquatech’s industry-leading technology portfolio includes membrane, thermal, biological, electrochemical and ultrapure water treatment solutions.

The agreement establishes a non-exclusive framework for collaboration on PFAS treatment projects worldwide, enabling both companies to combine their complementary technologies to better serve the rapidly growing PFAS remediation market.

Aquatech International’s corporate headquarters is located in Canonsburg, Pennsylvania, Established in 1981, the company is a global leader in water purification technology for industrial and infrastructure markets, specializing in desalination, water reuse, and zero liquid discharge.

“Coupling BioLargo’s AEC PFAS collection and concentration technology with Aquatech’s PFAS removal and destruction expertise presents a powerful opportunity to fast-track effective solutions to serve the customer,” said Devesh Mittal, vice president of Aquatech Environmental Services.

Henry DeVries is a former Forbes online columnist who is the chief book strategist at Indie Books International. He has ghostwritten, co-authored, or edited more than 200 business books, including his international bestseller, How to Close a Deal Like Warren Buffett*.*

https://calbizjournal.com/biolargo-signs-deal-to-accelerate-commercialization-of-pfas-treatment-technology/